Department of Preventive Medicine, University of Southern California, Los Angeles.
Department of Psychology, University of Southern California, Los Angeles.
JAMA Netw Open. 2020 Jan 3;3(1):e1919792. doi: 10.1001/jamanetworkopen.2019.19792.
While a diverse array of cannabis products that may appeal to youth is currently available, it is unknown whether the risk of persistent cannabis use and progression to higher frequency of use after experimentation differs among cannabis products.
To estimate the comparative relative risk of experimental use of 5 cannabis products on use status and frequency of use among adolescents during 12 months of follow-up.
DESIGN, SETTING, AND PARTICIPANTS: In this cohort study, data were collected from 3065 adolescents at 10 high schools in southern California, with baseline data collected in spring 2016, when students were in 11th grade, and 6-month and 12-month follow-up surveys collected in fall 2016 and spring 2017, when students were in 12th grade. Analyses, conducted from April to June 2019, were restricted to 2685 participants who were light or nonusers of any cannabis product (ie, ≤2 days in the past 30 days) at baseline.
Number of days of use of each cannabis product (ie, combustible, blunts, vaporized, edible, or concentrated) in the past 30 days at baseline (ie, 1-2 vs 0 days).
Past 6-month use (ie, yes vs no) and number of days of use in the past 30 days at 6-month and 12-month follow-ups for each product.
Of 2685 individuals in the analytic sample, 1477 (55.0%) were young women, the mean (SD) age was 17.1 (0.4) years, and a plurality (1231 [46.6%]) were Hispanic individuals. Among them, 158 (5.9%) reported combustible cannabis use on 1 to 2 days of the past 30 days at baseline, 90 (3.4%) reported blunt use, 78 (2.9%) reported edible cannabis use, 17 (0.6%) reported vaping cannabis, and 15 (0.6%) reported using cannabis concentrates. In regression models adjusting for demographic characteristics and poly-cannabis product use, statistically stronger associations of baseline use with subsequent past 6-month use at the 6-month and 12-month follow-ups were observed for combustible cannabis use (odds ratio, 6.01; 95% CI, 3.66-9.85) and cannabis concentrate use (odds ratio, 5.87; 95% CI, 1.18-23.80) compared with use of blunts (OR, 2.77; 95% CI, 1.45-5.29) or edible cannabis (OR, 3.32; 95% CI, 1.86-5.95) (P for comparison < .05); vaporized cannabis use (OR, 5.34; 95% CI, 1.51-11.20) was not significantly different from the other products. In similarly adjusted models, we found the association of cannabis use at baseline with mean days of use at the 6-month and 12-month follow-ups was significantly stronger for cannabis concentrate than for other cannabis products; participants who had used cannabis concentrate on 1 to 2 of the past 30 days at baseline (vs 0 days) used cannabis concentrate a mean of 9.42 (95% CI, 2.02-35.50) more days in the past 30 days at the 6-month and 12-month follow-ups (P for comparison < .05).
Cannabis control efforts should consider targeting specific cannabis products, including combustible cannabis and cannabis concentrate, for maximum public health consequences.
目前市场上有各种各样可能吸引年轻人的大麻产品,但是我们还不知道在经历实验后,不同大麻产品持续使用的风险以及使用频率上升的风险是否存在差异。
在 12 个月的随访期间,估计青少年在实验性使用 5 种大麻产品后,持续使用大麻的相对风险以及使用频率。
设计、地点和参与者:在这项队列研究中,数据来自南加州 10 所高中的 3065 名青少年,在 2016 年春季(学生在 11 年级)进行基线数据收集,在 2016 年秋季和 2017 年春季(学生在 12 年级)进行 6 个月和 12 个月的随访调查。从 2019 年 4 月到 6 月进行分析,仅纳入 2685 名基线时任何大麻产品(即过去 30 天≤2 天)轻或非使用者。
基线时过去 30 天内每种大麻产品(即可燃型、钝器型、汽化型、食用型或浓缩型)的使用天数(1-2 天与 0 天)。
过去 6 个月的使用情况(即有 vs 无)以及在 6 个月和 12 个月随访时过去 30 天的使用天数。
在分析样本的 2685 名个体中,1477 名(55.0%)为年轻女性,平均(SD)年龄为 17.1(0.4)岁,大多数(1231 名[46.6%])为西班牙裔个体。其中,158 名(5.9%)报告在过去 30 天内的 1-2 天内使用可燃型大麻,90 名(3.4%)报告使用钝器型大麻,78 名(2.9%)报告使用食用型大麻,17 名(0.6%)报告使用汽化型大麻,15 名(0.6%)报告使用浓缩型大麻。在调整人口统计学特征和多种大麻产品使用的回归模型中,与使用钝器型大麻(优势比,2.77;95%置信区间,1.45-5.29)或食用型大麻(优势比,3.32;95%置信区间,1.86-5.95)相比,基线时使用可燃型大麻(优势比,6.01;95%置信区间,3.66-9.85)和浓缩型大麻(优势比,5.87;95%置信区间,1.18-23.80)与随后的过去 6 个月使用情况有更强的关联(P<0.05);汽化型大麻的使用(优势比,5.34;95%置信区间,1.51-11.20)与其他产品无显著差异。在同样调整的模型中,我们发现与基线时的大麻使用情况相比,与使用浓缩型大麻相比,使用其他大麻产品与 6 个月和 12 个月随访时的平均使用天数的关联明显更强;与基线时(0 天)相比,在过去 30 天内的 1-2 天内使用浓缩型大麻的参与者在 6 个月和 12 个月的随访中平均多使用浓缩型大麻 9.42(95%置信区间,2.02-35.50)天(P<0.05)。
大麻控制工作应考虑针对特定的大麻产品,包括可燃型大麻和浓缩型大麻,以产生最大的公共卫生影响。